| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.16 | 20.8% | 15.3% |
| Total Income | 1.16 | 20.8% | 15.3% |
| Expenditure | 3.74 | 17.3% | 19.9% |
| PBT | — | ||
| Net Profit | -2.57 | 27.8% | 48.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.20 | 61.5% | 74.7% |
Ensysce Biosciences Reports Q2 2026 Financial Results and Business Highlights
14 Aug 2026 · 14 Aug, 1:56 am
Summary
Ensysce Biosciences reported its financial and operational results for the second quarter ended June 30, 2026. The company completed the acquisition of Cy Biopharma, adding CY200 for Complex Regional Pain Syndrome and securing significant new funding, extending cash runway into late 2027. Research and development expenses increased due to clinical activity, while the net loss attributable to common stockholders widened to $2.6 million from $1.7 million in the prior year's quarter. Management highlighted the strategic importance of the Cy Biopharma acquisition and progress on its PF614-MPAR program.
Key Highlights
- 1
Ensysce Biosciences completed the acquisition of Cy Biopharma, adding CY200 for Complex Regional Pain Syndrome and securing up to $77 million in new funding.
- 2
The company has cash runway into late 2027, with a potential second financing tranche extending it into 2028 upon achievement of clinical milestones.
- 3
Funding under federal grants totaled $1.2 million for the second quarter of 2026, a decrease from $1.4 million in the comparable year-ago quarter.
- 4
Research and development expenses increased by $0.5 million to $2.5 million for the second quarter of 2026 compared to the same period in 2025, primarily due to increased clinical activity for PF614.
- 5
General & administrative expenses were $1.3 million in the second quarter of 2026, a slight increase from $1.2 million in the second quarter of 2025.
- 6
Net loss attributable to common stockholders for the second quarter of 2026 was $2.6 million, compared to a net loss of $1.7 million for the second quarter of 2025.
- 7
The company strengthened its intellectual property position for MPAR® with a patent issued in Taiwan extending protection through 2042.
Management Comments
Dr. Lynn Kirkpatrick
Cy Biopharma’s neuroplastogenic approach to complex pain was the most compelling strategic opportunity we explored, and we believe this acquisition represents a significant value creation opportunity for Ensysce stockholders. The concurrent private placement financing was intentionally sized to support our immediate strategic objectives while maintaining financial discipline and allow us to progress our lead candidate in a pain market valued over $1 billion for which there is currently no approved therapy. During the second quarter of 2026 we also advanced the clinical development of PF614-MPAR, the first opioid engineered with built-in overdose protection. To support this clinical development, we were awarded the third year of funding under a $15.1 million grant from the National Institute on Drug Abuse (NIDA), completing the award, a powerful vote of confidence from a leading federal agency that has backed this program with two major awards totaling over $26 million over six years.
Informational and educational content only. Not investment advice.